Author Archive

Deadly Meat Allergy

http://

Deadly Meat Allergy

A man suddenly has a cardiac arrest at home and the cause of his medical emergency is a mystery! Let’s solve the mystery together and learn about shock, septic shock, anaphylactic allergies and more!  Scroll to about the 14 minute mark to finally hear he has Alpha Gal.

This video was adapted from a published medical case report: https://www.ncbi.nlm.nih.gov/pmc/arti…

For more:

It’s far from straight-forward just like Lyme/MSIDS.  So many unknowns.
 

 

Frightening V-Safe Data Yet CDC Green Lights 9th Dose While Downgrading COVID to the Same Severity As the Flu

https://thehighwire.com/ark-videos/the-clot-thickens/  Video Here

EPISODE 360: THE CLOT THICKENS

The V-safe Free-Text Data is Out and Aaron Siri, esq., Has the Details; Jefferey Jaxen reports on the state of vaccine mandates and informed consent in a post-COVID world, and a new vaccine technology beyond injectables that takes it a step too far; The Clot Thickens As A New Study The Severity of The Blood Clot Problem; Funeral director and embalmer’s firsthand account corroborates Haviland’s survey data.

Guests: Aaron Siri, Esq., Thomas Haviland, Richard Hirschman

AIRDATE: February 22, 2024

https://www.dossier.today/p/dose-number-nine-cdc-panel-green

CDC Panel Green Lights Ninth Dose of COVID-19 mRNA

It’s official: the Pfizer loyalty card has become a reality. Nine shots in three years.

Feb. 29, 2024
By Jordan Schachtel
 

For the Americans out there who remain true to the CDC’s vaccine recommendation schedule, you’ll be heading over to your local clinic in the coming weeks for another dose of Pfizer or Moderna’s mRNA Covid gene serum.

On Wednesday, the CDC recommended that seniors get another “booster” in the Spring, making this the ninth dose for Americans who continue to abide by the Government Health booster guidance schedule.

In just three year’s time, the CDC’s vaccine advisory committee has now authorized nine separate injections of a shot that was once advertised as the cure to the coronavirus. (See link for article)

______________

**UPDATE**

According to this, a strain will be chosen for a fall COVID shot people can get simultaneously with the flu shot. Problem is, both are ineffective, dangerous, deadly, and cause antibody dependent enhancement (ADE) or pathogenic priming. Neither prevents the spread of illness.

SUMMARY:

  • The 9th shot will soon be authorized for all ages
  • It targets the Eris variant (EG.5) which no longer exists
  • Big Pharma has conducted shabby studies to keep the narrative that the new shots offer “protection” from the latest variants despite these variants not being detected when the shots were being formulated,
  • The CDC continues to ignore research showing negative effectiveness and observable adverse events.
  • The CDC is ignoring all studies showing that the boosted are more likely to get COVID than the unvaccinated.  

______________

http://  Approx. 8 Min

Trustworthy Lies Are Good For You!

Once again, JP gives truth comedically.

https://www.thegatewaypundit.com/2024/03/cdc-downgrades-covid-same-severity-as-flu-says/

CDC Downgrades COVID to Same Severity as the Flu… But Says You Must Keep Having Vaccines

The Centers for Disease Control and Prevention (CDC) has downgraded the severity of the Chinese coronavirus to the same status as the flu, calling for a “unified approach” to treating such conditions.

In a press release on Friday, the CDC announced it was simplifying its recommendations for treating COVID because the virus no longer presents a significant threat.

The release stated:

CDC released today updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19.

The new guidance brings a unified approach to addressing risks from a range of common respiratory viral illnesses, such as COVID-19, flu, and RSV, which can cause significant health impacts and strain on hospitals and health care workers.

CDC is making updates to the recommendations now because the U.S. is seeing far fewer hospitalizations and deaths associated with COVID-19 and because we have more tools than ever to combat flu, COVID, and RSV.

(See link for article)

__________________

SUMMARY:

  • Predictably, the CDC takes credit for lessening the severity of COVID despite banning successful treatments which cost approximately 500,000 lives and pushing the ineffective and unsafe COVID gene therapy shots which cost approximately 17 MILLION lives.
  • Predictably, the CDC recommends ‘vaccination,’ treatment, and staying home, but fails to mention treatments that actually work that they banned.
  • Please remember the old, cheap trick of ignoring cases and deaths in the “vaccinated,” biasing estimates of efficacy for transmission that have been utilized.
  • The agency urges getting ‘vaccinated’ to prevent serious illness, hospitalization, and death despite the shots failing on each of those accounts as well as causing more adverse reactions and death than any other vaccine in the history of VAERS.
  • The agency revised the guidelines on isolation for those who test positive for the illness, but urged people to continue wearing face masks and practice social distancing regardless, despite the danger and fruitlessness of these endeavors.  
Sadly, epidemiologists that have been ruthlessly censored and banned have been sounding the alarm on this since the start of the COVID PsyOp :

Again, the CDC is beyond hope and rehabilitation and should be eliminated.

Senate Panel on ‘Vaccines’- The Red Pill We’ve All Been Waiting for

https://www.midwesterndoctor.com/p/this-senate-panel-on-the-vaccines

This Senate Panel On The Vaccines Is The Red Pill We’ve All Been Waiting For

This excellent presentation meticulously breaks down exactly what went awry throughout COVID-19. What everyone needs to know is summarized below.

Article Excerpt:

A lot of work has gone into producing each of the vaccine panels he’s hosted. On Monday, he hosted “Federal Health Agencies and the COVID Cartel: What Are They Hiding?” When it was all said and done, I believe this panel was the most effective presentation I have seen for explaining what happened throughout COVID-19 and waking people up to how much they have been lied to. Because of this I strongly encourage you to watch or share his presentation with people who you think might be open to understanding exactly what was done to all of us. This article will begin with his entire panel:

Lastly, for those who prefer to read, a transcript of Johnson’s symposium can be found here (See link for article and videos)

_______________

**Comment**

Admittedly, the article is long; however, there’s a lot of history to record.

The author took a lot of time to highlight important parts. Video highlights include:

  • Edward Dowd’s work on excess deaths
  • Kevin McKernan’s discovery of DNA plasmid contamination and its connection with cancer
  • Dr. Harvey Risch’s overview of the bioweapons industry
  • Barbara Loe Fisher’s work with vaccine advocacy
  • Brian Hooker’s 23 years of work (15 peer-reviewed papers) on vaccine injuries
  • Del Bigtree’s decade of vaccine advocacy work
  • Dr. Sabine Hazan’s work on existing therapies to treat COVID
  • Dr. Pierre Kory’s work on repurposed drugs for COVID
  • Dr. Christian Perron’s work showing how HCQ and azithromycin lowered COVID death rate got him fired from his 26 year professorship.
  • Raphael Lataster, a leading researcher exposing fraud within COVID vaccine trials
  • Journalist Lara Logan exposed how journalism has been hijacked by the government
  • Matthias Desmet gave a summary of crowd psychology
  • Brett Weinstein talked about malicious forces taking away truth and justice

And many, many more.

Note: for anyone considering being a whistleblower, Johnson requested for you to contact his office here.

The article above is written by A Midwestern Doctor, an experienced doctor who wishes to remain anonymous for obvious reasons. I highly recommend subscribing to this particular Substack as it is very informative and one of the few places you will hear details mainstream media and ‘science’ omit such as:

Novel Lyme Antibiotic Heads For Human Safety Trials

https://news.northeastern.edu/2024/02/28/lyme-antibiotic-treatment-human-trials/

Experimental antibiotic treatment for Lyme heads for human safety trials

By Cynthia McCormick Hibbert, Northeastern University

2/28/24

Human safety trials of a novel antibiotic treatment for Lyme disease developed by Northeastern professor Kim Lewis are scheduled to start this spring in Australia, with results anticipated by fall.

“Hopefully, the results will be positive,” says Lewis, University Distinguished Professor of Biology.

So far the therapeutic agent, an antibiotic known as hygromycin A, has not been toxic in animals and has cleared Lyme in mice, he says.

Existing standard treatments for Lyme disease, doxycycline and amoxicillin, have proved far from silver bullets for the nearly half-million people stricken by the tick-borne illness in the U.S. each year.

The Centers for Disease Control and Prevention estimates that 5% to 10% of Lyme patients have persistent symptoms after early treatment, while the Global Lyme Alliance says that as many as 2 million Americans could suffer post-treatment disability.

Overlooked antibiotic

Lewis says that hygromycin A is different from the broad spectrum antibiotics in that it specifically targets spirochetes including Borrelia burgdorferi, the spiral-shaped bacterium that transmits Lyme disease through the bite of a deer tick.

The expectation is not only that hygromycin A will prove more effective in curing Lyme disease in the early, acute stage but that it could also mop up residual pathogens that may persist in some patients with chronic disease, Lewis says.

He suspects many cases of chronic Lyme symptoms are caused by changes to patients’ microbiomes due to the use of broad spectrum antibiotics.

With hygromycin’s specific targeting of spirochetes, Lewis says that is less likely to lead to chronic disease.

“What we’re testing for now is a treatment for acute Lyme that will be more effective and won’t wreck the microbiome and will hopefully lead to fewer chronic cases,” he says.

People with chronic, long-term or persistent Lyme call it a life-changing experience, leaving them with arthritis, cardiac problems, fatigue, brain fog, depression and anxiety.

Made by a bacterium found in the soil, hygromycin A has been a known but overlooked antimicrobial since 1953, Lewis says.

“Nobody really cared about this compound because it’s very weak against regular bacteria. What we discovered is that it is indeed very weak against regular pathogens but exceptionally potent against spirochetes.”

Phase 1 trials set for April

Lewis’ team has licensed the compound to Flightpath, a biotech company focused on Lyme disease that is conducting the phase 1 trial scheduled to start in April. Flightpath is leading the clinical development effort with funding from the Cohen Foundation.

“A safety trial simply asks the question, ‘Is it safe for healthy people to take this drug,’” Lewis says.

If it passes toxicity screenings, it can advance to phase 2 to determine effective dosing ranges “and see if it cures acute Lyme disease,” he says.

Success at that stage would lead to a clinical trial involving a larger group of patients, with the possible end result of requesting FDA approval for the treatment via a new drug application.

Even if approved, human efficacy trials probably wouldn’t start until 2025, Lewis says.

That hasn’t stopped the Global Lyme Alliance, which helped fund Lewis’ Lyme drug discovery program, from expressing excitement over the prospect of seeing hygromycin A in doctors’ hands.

In a statement on Instagram in February, the alliance quoted Flightpath CEO Matt Tindall saying that reaching this stage is a “landmark achievement for Lyme patients.”

If the trials make it to phase 2, researchers will reach out to Lyme specialists at places such as Johns Hopkins and Massachusetts General Hospital to recruit Lyme patients for the study, Lewis says.

Most projects that researchers in academia and industry toil on for years “do not get to the point when we feel, based on extensive animal studies, that the compound has sufficient efficacy and safety features that we can now introduce it into humans,” Lewis says.

“We are at that point with hygromycin A. That is, of course, encouraging,” he says.

SOURCE: Northeastern University

______________

For more:

Military Report: Most Frequently Diagnosed Vector-borne Diseases

https://health.mil/News/Articles/2024/01/01/MSMR-Vector-Diseases

Brief Report: The Four Most Frequently Diagnosed Vector-borne Diseases Among Service Member and Non-Service Member Beneficiaries in the Geographic Combatant Commands, 2010–2022

Vector-borne diseases may pose an increased risk for U.S. service members during recurring military training exercises, operations, and response missions, in addition to residence in endemic regions within and outside the continental U.S.1,2 Prior MSMR reports address VBD surveillance, described by surveillance data for 23 reportable medical events, among active duty and reserve component service members.3,4 This report covers a 13-year surveillance period, from January 2010 to December 2022, and provides linear trends of selected VBDs among Armed Forces service and non-service member beneficiaries diagnosed at installations within the Northern Command (NORTHCOM), Africa Command (AFRICOM), Central Command (CENTCOM), European Command (EUCOM), Indo-Pacific Command (INDOPACOM), or Southern Command (SOUTHCOM). Trends of only the four most frequently reported VBDs were evaluated, as Lyme disease, malaria, Rocky Mountain Spotted Fever, and dengue fever comprised 90% (n=5,199) of all 23 VBDs (n=5,750) among Military Health System beneficiaries documented as RMEs during the surveillance period.

Methods

This study includes all MHS beneficiaries from January 2010 through December 2022. Data were acquired from RME records of 23 VBDs from the Defense Medical Surveillance System, limited to the four most-diagnosed VBDs in DMSS during the surveillance period; a full listing of VBD RMEs are available in a prior MSMR report.3 A VBD case was defined as an individual identified through a RME report, classified as “confirmed,” “probable,” or “suspect” by having met specified laboratory or epidemiologic criteria.5

Demographic information including military component (active, reserve, guard), beneficiary status (service members or non-service member), and U.S. Combatant Command at time of diagnoses were included. Non-service member beneficiaries included dependents, former service members, and retirees. MHS beneficiaries diagnosed as a case before the surveillance period were excluded. An individual could qualify as a case once for each RME type. Incidence date was the earliest event date, with classification determined by utilizing all available data, prioritizing confirmed over probable or suspect records.

Results

Click on the table to access a 508-compliant PDF versionClick on the table to access a 508-compliant PDF version

A total of 5,199 confirmed, probable, and suspect cases of Lyme disease (n=3,400), RMSF (n=893), malaria (n=679), and dengue fever (n=227) were identified among MHS beneficiaries from January 2010 through December 31, 2022 (Table). Of those confirmed, probable, and suspect cases, 2,343 were diagnosed in service members and 2,918 were diagnosed in non-service member beneficiaries (data not shown). Lyme disease and RMSF, both caused by tick-borne pathogens, accounted for 83% of cases, while malaria and dengue fever, transmitted by mosquito vectors, comprised the remainder.

Since Lyme disease was the most common VBD of the four diseases evaluated during the surveillance period, trends of confirmed and probable cases of Lyme disease over time by CCMD are presented in the Figure. Confirmed Lyme disease cases peaked in 2012 (n=455) and then gradually decreased over the study period to a low of 75 cases in 2022; probable cases peaked in 2017 (n=53) and steadily decreased to a low of 15 cases in 2022; suspect cases peaked in 2016 (n=73) and progressively declined to a low of 8 cases in 2022 (data not shown). Cases from NORTHCOM represented the greatest number of confirmed and probable Lyme disease cases during the entire surveillance period (Figure). The annual number of confirmed and probable Lyme disease cases from EUCOM were greatest in 2011 and lowest in 2017; Lyme cases were very low in all other CCMDs, ranging from 0 to 6 cases annually (data not shown).

The Atlantic and central regions of the U.S contributed 85% of NORTHCOM’s reported RMSF cases (data not shown). NORTHCOM averaged 30 RMSF cases annually between 2010 and 2016, dramatically increasing to an average of 149 cases between 2017 and 2019 (data not shown). NORTHCOM was only able to confirm 32% of RMSF cases reported during the surveillance period (Table).

Discussion

Lyme disease cases constituted the largest proportion of overall RMEs in this report, with highest numbers occurring in 2012. A substantial proportion of Lyme disease cases were reported from locations in the northeastern U.S., where Lyme disease is known to be endemic: 43% of service members and non-service beneficiaries were diagnosed at NORTHCOM Groton (New London Submarine Base, CT) and NORTHCOM New England. The New London Submarine Base is close to Lyme, Connecticut, where an epidemiological evaluation of a cluster of children with arthritis resulted in the first complete description of the infection in 1976, giving the disease its name.6 Connecticut still ranks in the top 10 states for reported Lyme disease cases.7 No Lyme disease cases were reported in AFRICOM during the surveillance period, because the vectors (Ixodes pacificus and Ixodes scapularis) are not present in the region.

In 2017, the armed forces expanded its RME guidelines to include all spotted fever rickettsioses (SFR), to better align with CDC case definitions.2 Diagnoses and reports of rickettsial diseases at military hospitals and clinics in NORTHCOM (where RMSF is endemic) significantly increased after the surveillance requirement expansion from only RMSF to the broader SFR group. In this review, all SFR cases were RMSF diagnoses (n=893).

Approximately 68% of RMSF cases reported during the surveillance period could not be confirmed. All laboratory tests performed at military health facilities for RMSF were Indirect Fluorescent Antibody (IFA) assay and other antibody tests, and no records of testing with PCR of blood or eschar specimens were found. Definite identification of Rickettsiae is not feasible solely by IFA due to considerable serologic cross-reactivity, particularly when high-endpoint titers are seen for more than 1 rickettsial antigen.8 Increased use of molecular assays (i.e., real-time PCR) can both confirm and offer species-specific diagnosis in a single sample, facilitating identification and management of rickettsial diseases in both service members and non-service beneficiaries.

The observed decline in the incidence of mosquito-borne cases, such as malaria and dengue, among deployed service members over the last decade is likely due to reduced deployments to endemic regions, with the exception of EUCOM.4 Although dengue fever is not represented significantly in EUCOM in this study, there is a rising risk of dengue and other VBDs due to environmental changes and expanding global travel and trade.9,10,11

VBDs often manifest with non-specific symptoms, and when unconfirmed could constitute a number of other infections or health conditions. Lyme disease is frequently misdiagnosed as chronic fatigue syndrome, fibromyalgia, or multiple sclerosis. This non-specificity of symptoms and related issues such as diagnostic availability and cross-reactivity in diagnosis confirmation can pose challenges for accurate case identification and classification, resulting in the major limitations to this study’s findings.

This report summarizes data from electronic reports of RMEs and examines the incidence and geographic distribution of the top four vector-borne infectious diseases among service members and non-service MHS beneficiaries in the CCMDs during a recent 13-year period. Awareness of the risk of these VBDs will help senior leaders develop and employ strategies to decrease avertable medical problems in MHS beneficiaries, maximizing the productivity and readiness of the medical force.

Author Affiliations

Epidemiology and Disease Surveillance Department, U.S. Army Public Health Command–West, Joint Base San Antonio–Fort Sam Houston, TX: Dr. Stidham; Human Health Services, U.S. Public Health Command–Pacific, Tripler, HI: COL Cole; Epidemiology and Analysis Branch, Armed Forces Health Surveillance Division, Defense Health Agency: Dr. Mabila

(See link for article and graphs)

________________

For more: